After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
Manuel Pombo‐Suárez, Carlos Sánchez‐Piedra, Juan J. Gómez‐Reino, Kim Lauper, Denis Mongin, Florenzo Iannone, Karel Pavelká, Dan Nordström, Nevsun İnanç, Cătălin Codreanu, Kimme L Hyrich, D. Choquette, Anja Strangfeld, Burkhard F. Leeb, Žiga Rotar, Ana Maria Rodrigues, Eirik Klami Kristianslund, Tore K Kvien, Ori Elkayam, G. Lukina, Sytske Anne Bergstra, Axel Finckh, Delphine S. Courvoisier
Topics & Concepts
MedicineRheumatoid arthritisProportional hazards modelCohortTofacitinibInternal medicineConfoundingAdverse effectDemographySociologyRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsBiosimilars and Bioanalytical Methods